References
[1]. Sheikh, M., Roshandel, G., McCormack, V., & Malekzadeh, R. (2023). Current status and future prospects for esophageal cancer. Cancers, 15(3), 765.
[2]. Li, J., Xu, J., Zheng, Y., Gao, Y., He, S., Li, H., ... & He, J. (2021). Esophageal cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research, 33(5), 535.
[3]. Napier, K. J., Scheerer, M., & Misra, S. (2014). Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World journal of gastrointestinal oncology, 6(5), 112.
[4]. Testa, U., Castelli, G., & Pelosi, E. (2023). The molecular characterization of genetic abnormalities in esophageal squamous cell carcinoma may foster the development of targeted therapies. Current Oncology, 30(1), 610-640.
[5]. Zhang, W., Bailey-Wilson, J. E., Li, W., Wang, X., Zhang, C., Mao, X., ... & Wu, M. (2000). Segregation analysis of esophageal cancer in a moderately high–incidence area of northern China. The American Journal of Human Genetics, 67(1), 110-119.
[6]. Sohda, M., & Kuwano, H. (2017). Current status and future prospects for esophageal cancer treatment. Annals of Thoracic and Cardiovascular Surgery, 23(1), 1-11.
[7]. Tang, G. Y., Meng, X., Gan, R. Y., Zhao, C. N., Liu, Q., Feng, Y. B., ... & Li, H. B. (2019). Health functions and related molecular mechanisms of tea components: an update review. International journal of molecular sciences, 20(24), 6196.
[8]. Gao, Y. T., McLaughlin, J. K., Blot, W. J., Ji, B. T., Dai, Q., & Fraumeni, J. F. (1994). Reduced risk of esophageal cancer associated with green tea consumption. JNCI: Journal of the National Cancer Institute, 86(11), 855-858.
[9]. Trisha, A. T., Shakil, M. H., Talukdar, S., Rovina, K., Huda, N., & Zzaman, W. (2022). Tea polyphenols and their preventive measures against cancer: Current trends and directions. Foods, 11(21), 3349.
[10]. Sekula, P., Fabiola Del Greco, M., Pattaro, C., & Köttgen, A. (2016). Mendelian randomization as an approach to assess causality using observational data. Journal of the American Society of Nephrology, 27(11), 3253-3265.
[11]. Taschler, B., Smith, S. M., & Nichols, T. E. (2022). Causal inference on neuroimaging data with Mendelian randomisation. NeuroImage, 258, 119385.
[12]. Bowden, J., & Holmes, M. V. (2019). Meta‐analysis and Mendelian randomization: a review. Research synthesis methods, 10(4), 486-496.
[13]. Bucur, I. G., Claassen, T., & Heskes, T. (2020). Inferring the direction of a causal link and estimating its effect via a Bayesian Mendelian randomization approach. Statistical Methods in Medical Research, 29(4), 1081-1111.
[14]. Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., ... & Haycock, P. C. (2018). The MR-Base platform supports systematic causal inference across the human phenome. eLife, 7, e34408.
[15]. Deng, Y., Ge, W., Xu, H., & Zhang, J. (2022). A Mendelian randomization study of the effect of tea intake on breast cancer. Frontiers in Nutrition, 9, 956969.
[16]. Chen, S., Chen, T., Chen, Y., Huang, D., Pan, Y., & Chen, S. (2022). Causal association between tea consumption and bone health: a mendelian randomization study. Frontiers in Nutrition, 9, 872451.
[17]. Sun, Q., Gao, N., Song, J., Jia, J., Dong, A., & Xia, W. (2024). The association between tea consumption and non-malignant digestive system diseases: a Mendelian randomized study. Clinical Nutrition ESPEN, 60, 327-332.
[18]. Kim, Y., & Je, Y. (2024). Tea consumption and risk of all-cause, cardiovascular disease, and cancer mortality: a meta-analysis of thirty-eight prospective cohort data sets. Epidemiology and Health, 46, e2024056.
Cite this article
Deng,S.;Zeng,H.;Zhou,P.;Guo,Z. (2025). A Mendelian randomization study reveals a causal relationship between tea consumption and esophageal cancer. Journal of Clinical Technology and Theory,3(2),23-29.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Journal:Journal of Clinical Technology and Theory
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).
References
[1]. Sheikh, M., Roshandel, G., McCormack, V., & Malekzadeh, R. (2023). Current status and future prospects for esophageal cancer. Cancers, 15(3), 765.
[2]. Li, J., Xu, J., Zheng, Y., Gao, Y., He, S., Li, H., ... & He, J. (2021). Esophageal cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research, 33(5), 535.
[3]. Napier, K. J., Scheerer, M., & Misra, S. (2014). Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World journal of gastrointestinal oncology, 6(5), 112.
[4]. Testa, U., Castelli, G., & Pelosi, E. (2023). The molecular characterization of genetic abnormalities in esophageal squamous cell carcinoma may foster the development of targeted therapies. Current Oncology, 30(1), 610-640.
[5]. Zhang, W., Bailey-Wilson, J. E., Li, W., Wang, X., Zhang, C., Mao, X., ... & Wu, M. (2000). Segregation analysis of esophageal cancer in a moderately high–incidence area of northern China. The American Journal of Human Genetics, 67(1), 110-119.
[6]. Sohda, M., & Kuwano, H. (2017). Current status and future prospects for esophageal cancer treatment. Annals of Thoracic and Cardiovascular Surgery, 23(1), 1-11.
[7]. Tang, G. Y., Meng, X., Gan, R. Y., Zhao, C. N., Liu, Q., Feng, Y. B., ... & Li, H. B. (2019). Health functions and related molecular mechanisms of tea components: an update review. International journal of molecular sciences, 20(24), 6196.
[8]. Gao, Y. T., McLaughlin, J. K., Blot, W. J., Ji, B. T., Dai, Q., & Fraumeni, J. F. (1994). Reduced risk of esophageal cancer associated with green tea consumption. JNCI: Journal of the National Cancer Institute, 86(11), 855-858.
[9]. Trisha, A. T., Shakil, M. H., Talukdar, S., Rovina, K., Huda, N., & Zzaman, W. (2022). Tea polyphenols and their preventive measures against cancer: Current trends and directions. Foods, 11(21), 3349.
[10]. Sekula, P., Fabiola Del Greco, M., Pattaro, C., & Köttgen, A. (2016). Mendelian randomization as an approach to assess causality using observational data. Journal of the American Society of Nephrology, 27(11), 3253-3265.
[11]. Taschler, B., Smith, S. M., & Nichols, T. E. (2022). Causal inference on neuroimaging data with Mendelian randomisation. NeuroImage, 258, 119385.
[12]. Bowden, J., & Holmes, M. V. (2019). Meta‐analysis and Mendelian randomization: a review. Research synthesis methods, 10(4), 486-496.
[13]. Bucur, I. G., Claassen, T., & Heskes, T. (2020). Inferring the direction of a causal link and estimating its effect via a Bayesian Mendelian randomization approach. Statistical Methods in Medical Research, 29(4), 1081-1111.
[14]. Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., ... & Haycock, P. C. (2018). The MR-Base platform supports systematic causal inference across the human phenome. eLife, 7, e34408.
[15]. Deng, Y., Ge, W., Xu, H., & Zhang, J. (2022). A Mendelian randomization study of the effect of tea intake on breast cancer. Frontiers in Nutrition, 9, 956969.
[16]. Chen, S., Chen, T., Chen, Y., Huang, D., Pan, Y., & Chen, S. (2022). Causal association between tea consumption and bone health: a mendelian randomization study. Frontiers in Nutrition, 9, 872451.
[17]. Sun, Q., Gao, N., Song, J., Jia, J., Dong, A., & Xia, W. (2024). The association between tea consumption and non-malignant digestive system diseases: a Mendelian randomized study. Clinical Nutrition ESPEN, 60, 327-332.
[18]. Kim, Y., & Je, Y. (2024). Tea consumption and risk of all-cause, cardiovascular disease, and cancer mortality: a meta-analysis of thirty-eight prospective cohort data sets. Epidemiology and Health, 46, e2024056.